Luke Miels
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its lung cancer pipeline, in what would be the British drugmaker's largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. The Financial Times had reported the transaction earlier on Tuesday.